ARAMCHOL NCT02279524


Laboratory : GALMED

Study Name : 

Phase 2

Study Number : NCT02279524

Number of patients recruited : 240

Probability to be under placebo : 33%

Contacts : 

Contact: Tali Gorfine, MD. PhD. +972-3-6938448 ext 3723

tali@galmedpharma.com


Contact: George Tonelli   1-845-3231819

george@galmedpharma.com










Share on StockTwits

WWW.NASHBIOTECHS.COM  -  Copyright G DIVRY 2015-2016  - Contact and TERMS OF USE